Anixa Biosciences (ANIX) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Anixa Biosciences (ANIX) has outperformed Stablecoin Development (SDEV) over the past year, losing 34.5% versus a loss of 66.8%. Over five years, ANIX leads with a -33.7% price change compared with -99.9% for SDEV. Stablecoin Development is the larger company by market cap ($103.0 million vs $101.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | SDEV |
|---|---|---|
| Share price | $2.91 | $1.99 |
| Market cap | $101.16M | $102.99M |
| 1-day change | -1.36% | -28.42% |
| YTD return | -6.73% | -92.94% |
| 1-year return | -34.46% | -66.83% |
| 5-year return | -33.71% | -99.94% |
| EPS (TTM) | $-0.32 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $99.75 |
| 52-week low | $2.32 | $0.78 |
| Distance from 52-week high | -46.70% | -98.01% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +235.05% | — |
| Average volume | 302.95K | 11.74M |
| Shares outstanding | 34.76M | 51.75M |
| Employees | 4 | 2 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIX has outperformed SDEV by 32.4 percentage points over the past year.
- The two companies sit in different sectors: Anixa Biosciences in Healthcare and Stablecoin Development in Health Care.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Healthcare · Biotechnology · 4 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ANIX vs SDEV FAQ
Which is bigger, Anixa Biosciences or Stablecoin Development?
Stablecoin Development (SDEV) is larger, with a market capitalization of $102.99M compared with $101.16M for Anixa Biosciences (ANIX).
Which stock has performed better over the past year, ANIX or SDEV?
ANIX returned -34.46% over the past 12 months, compared with -66.83% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Stablecoin Development in the same industry?
No. Anixa Biosciences is in the Healthcare sector, while Stablecoin Development is in Health Care.